CD8A and lung carcinoma: Analysis of 17,006 lung cancer patients from the FDA’s FAERS database revealed older patients not only experience more irAEs but also face higher toxicity levels (57), likely due to reduced CD8+ T cell counts associated with immune senescence (57, 58).